- Home
- MYO
MYO
Myomo Inc.
as 07-26-2024 4:00pm EST
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The Company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The Company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 92.5M | IPO Year: | 2017 |
| Target Price: | $7.00 | AVG Volume (30 days): | 878.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.27 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.50 - $5.64 | Next Earning Date: | 08-07-2024 |
| Revenue: | $19,548,839 | Revenue Growth: | 29.17% |
| Revenue Growth (this year): | 41.37% | Revenue Growth (next year): | 38.01% |
Stock Insider Trading Activity of Myomo Inc. (MYO)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| KIRK THOMAS F | MYO | Director | May 29 '24 | Buy | $3.50 | 50,000 | $175,000.00 | 236,499 | SEC Form 4 |
| Kovelman Harry | MYO | Chief Medical Officer | May 15 '24 | Sell | $3.69 | 35,426 | $130,838.85 | 98,009 | SEC Form 4 |
| KIRK THOMAS F | MYO | Director | Mar 14 '24 | Buy | $3.50 | 50,000 | $175,000.00 | 186,499 | SEC Form 4 |
| KIRK THOMAS F | MYO | Director | Nov 20 '23 | Buy | $3.10 | 50,000 | $155,000.00 | 136,499 | SEC Form 4 |
Latest Myomo Inc. News
MYO Breaking Stock News: Dive into MYO Ticker-Specific Updates for Smart Investing
Business Wire
19 days ago
Myomo Reports Preliminary Second Quarter 2024 Revenues and Operating Metrics
ACCESSWIRE
a month ago
Sidoti Events, LLC's Virtual June Small-Cap Conference
Yahoo Finance Video
2 months ago
FDA panel votes to recommend Eli Lilly's Alzheimer's drug
GlobeNewswire
2 months ago
Chu Vision Institute Unveils Comprehensive Guide to LASIK Recovery and Aftercare, Pioneering Patient Care in Minneapolis
Reuters
2 months ago
California seeks company profits in Big Oil climate lawsuit
USA TODAY
2 months ago
S&P 500, Nasdaq post record closing highs; Fed meeting, CPI ahead
GlobeNewswire
2 months ago
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
Business Wire
2 months ago
Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock
Compare MYO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MYO Myomo Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.